SIRT1 and atrial fibrillation: Consequently, while theoretical insights suggest that adding a SIRT1 inhibitor might reverse DAPA’s beneficial effects on fibrosis and AF, clinical studies are essential to validate these interactions and their impact on patient outcomes.